Adversarial Injection · Tisagenlecleucel (Kymriah; CTL019; BLA 125706; no conventional CAS — autologous living cell therapy; NIOSH HD Category 1; [ONE-HUNDRED-THIRD MECHANISM CLASS in Glyphward 676-attack portfolio — FIRST CAR-T (CHIMERIC ANTIGEN RECEPTOR T-CELL) THERAPY EVER FDA APPROVED / FIRST GENE THERAPY EVER FDA APPROVED IN THE UNITED STATES (BLA 125706 AUGUST 30 2017); LANDMARK APPROVALS: (1) FIRST CAR-T EVER: preceded all subsequent CAR-T approvals (axicabtagene Oct 2017 [2nd]; brexucabtagene Jul 2021 [3rd]; lisocabtagene Feb 2021 [4th]; idecabtagene Mar 2021 [5th]; ciltacabtagene Feb 2022 [6th]; obecabtagene Nov 2024 [7th/99th mechanism class]); (2) FIRST GENE THERAPY EVER FDA APPROVED IN US: ended 20+ year drought since 1993 Biologics License Application for gene therapy was submitted but none approved until tisagenlecleucel Aug 30 2017 — specifically: Novartis Kymriah was FDA's first ever gene therapy approval; sparked gene therapy revolution (spark therapeutics voretigene neparvovec Dec 2017 second gene therapy; bluebird bio betibeglogene Mar 2022 third; etc.); CTL019 ACADEMIC ORIGIN: University of Pennsylvania Department of Pathology and Laboratory Medicine / Abramson Cancer Center; PRINCIPAL INVESTIGATOR: Carl H. June MD (Richard W. Vague Professor in Immunotherapy; Penn Director CAR-T program; first to demonstrate clinical CAR-T efficacy in B-ALL 2011 [N Engl J Med 365:725, 2011; first pediatric CD19 CAR-T CR in Emily Whitehead age 7; sustained remission]); CTL019 CONSTRUCT: FMC63 ANTI-CD19 scFv (FMC63: murine monoclonal antibody; FITC-conjugated anti-CD19 clone; Kd ~2-3 nM FOR CD19 EXTRACELLULAR DOMAIN; HIGH AFFINITY/SLOW-OFF [vs SJ25C1 Kd ~28 nM in obe-cel]; VH3-15/Vκ3-20 germline; CDR sequences: CDRH3 ARDRVTITVAGDY; CDRL3 QQGNTLPYT; IgG1 isotype parent) → VL-(G4S)3-VH scFv + CD8α HINGE (41 AA) + CD8α TRANSMEMBRANE DOMAIN (23 AA) + CD137 (4-1BB; TNFRSF9) INTRACELLULAR COSTIMULATORY DOMAIN (42 AA; TRAF2/TRAF3/TRAF5 → NF-κB → T-CELL SURVIVAL/MEMORY/ANTI-APOPTOTIC BCL-2/BCL-XL; JNK/p38/AP-1 → cytokine; AKT/mTOR → metabolic reprogramming → memory T-cell) + CD3ζ SIGNALING DOMAIN (3 ITAMs × 2 NPXY MOTIFS EACH; ZAP70 ITAM pTyr → LAT → PLCγ1 → IP3/DAG → Ca²+/NFAT + PKCθ/NF-κB → full T-cell activation program); LENTIVIRAL VECTOR (SIN LV): SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR: HIV-1-derived backbone; U3 promoter deletion in 3'LTR → prevents full-length LTR transcription after integration → no replication-competent lentivirus; SFFV (spleen focus-forming virus) internal promoter → constitutive CAR expression; VSV-G (vesicular stomatitis virus glycoprotein) pseudotyped envelope → broad tropism; packaging by 4-plasmid system (gag/pol + rev + VSV-G + transfer plasmid); NOVARTIS LICENSE: Novartis licensed CTL019 from University of Pennsylvania (Carl June lab) for worldwide rights; collaborative agreement 2012; Novartis invested $20M+ in Penn partnership; pivotal trials executed by Novartis; BLA 125706 submitted 2017; FDA approved August 30 2017; ELIANA PHASE 2 (NCT02435849): STUDY POPULATION: pediatric and young adult patients 3 months to <25 years; R/R B-cell ALL after ≥2 prior lines or relapsed post-allo-HSCT; DOSE: 0.1-5.0 × 10⁶ CAR+ T cells/kg (weight-based; max 5.0 × 10⁸ CAR+ T cells); LYMPHODEPLETION: fludarabine 30 mg/m²/day × 3 days + cyclophosphamide 500 mg/m²/day × 2 days (or) cyclophosphamide alone 750 mg/m²/day × 1; ELIANA RESULTS: ORR 81% (CR/CRi); mDOR not reached at 12 months; MRD-NEGATIVE (flow cytometry 10⁻⁴ sensitivity) AMONG CR: 79%; 12-MONTH EVENT-FREE SURVIVAL (EFS): 50%; 12-MONTH OVERALL SURVIVAL (OS): 76%; CRS (PENN CRITERIA [Lee 2014] GRADE 3+): 46% — HIGH GRADE 3+ CRS INCIDENCE (vs obe-cel grade 3+ CRS 1.0% — attributed to FMC63 high-affinity slow-off tonic signaling → effector-prone T cells → stronger CRS); ICANS (FORMER NEUROTOXICITY): 13% grade 3+; JULIET PHASE 2 (NCT02445248): ADULT DLBCL; ORR 52%; CR 40%; 12-month DOR 65% among responders; NIOSH HD CATEGORY 1 ANTINEOPLASTIC; NO CONVENTIONAL CAS; OSHA NO PEL; NO ACGIH TLV; NO NIOSH REL; BLA 125706 → CORITY NULL; VELOCITYEHS NULL; EHS INSIGHT NULL; CTL019 FMC63 4-1BB LENTIVIRAL GENE THERAPY ABSENT; ELIANA ORR 81% ABSENT; FIRST GENE THERAPY ABSENT; NIOSH HD CAT 1 ABSENT ALL EHS DATABASES]) · First CAR-T Ever + First Gene Therapy Ever + FMC63 4-1BB Lentiviral + ELIANA B-ALL · Attack #676

Tisagenlecleucel (Kymriah; CTL019; BLA 125706; [ONE-HUNDRED-THIRD MECHANISM CLASS — FIRST CAR-T (CHIMERIC ANTIGEN RECEPTOR T-CELL) THERAPY EVER FDA APPROVED / FIRST GENE THERAPY EVER FDA APPROVED IN THE UNITED STATES (BLA 125706 AUGUST 30 2017); FMC63 scFv Kd ~2-3 nM + CD8α HINGE+TM + 4-1BB CD137 TRAF2/3/5→NF-κB + CD3ζ ITAM×3 + VSV-G SIN LENTIVIRAL; ELIANA PEDIATRIC B-ALL ORR 81% MRD-NEG 79%; NOVARTIS / UPENN CARL JUNE; NIOSH HD CATEGORY 1; NO CONVENTIONAL CAS]) — Novartis Pharmaceuticals Corporation East Hanover NJ (BLA 125706 holder; UPenn CTL019 license; no CAS → displayed BLA 125706), Lonza Pharma & Biotech Houston TX (commercial manufacturing CDMO Kymriah; lentiviral transduction; no CAS → displayed BLA 125706), and St. Jude Children's Research Hospital Memphis TN (ELIANA trial pediatric B-ALL site; no CAS → displayed BLA 125706) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (no conventional CAS — cell therapy) + First Gene Therapy Historic Significance Absent + FMC63 4-1BB Lentiviral Absent + ELIANA Results Absent: AI Prompt Injection via EHS Monitor Report AI

Tisagenlecleucel (Kymriah; CTL019; BLA 125706; NIOSH HD Category 1) is the one-hundred-third mechanism class in the Glyphward adversarial portfolio — simultaneously the first CAR-T cell therapy ever FDA approved and the first gene therapy ever FDA approved in the United States (BLA 125706 August 30 2017; ended a 20+ year gene therapy approval drought) — a historic first in oncology and gene therapy whose mechanism (FMC63 scFv 4-1BB SIN lentiviral) and occupational hazard profile remain entirely absent from Cority, VelocityEHS, and EHS Insight for BLA 125706.

Tisagenlecleucel as One-Hundred-Third Mechanism Class: First CAR-T and First Gene Therapy Ever FDA Approved

Tisagenlecleucel (Kymriah; CTL019; BLA 125706) represents the one-hundred-third mechanism class in the Glyphward portfolio: simultaneously the first chimeric antigen receptor T-cell (CAR-T) therapy ever FDA approved and the first gene therapy ever FDA approved in the United States (BLA 125706 August 30 2017; pediatric/young adult R/R B-cell ALL). HISTORICAL CONTEXT — GENE THERAPY DROUGHT: the first human gene therapy clinical trial was conducted in 1990 (adenosine deaminase severe combined immunodeficiency; ADA-SCID; French Anderson/Blaese/Culver group; NIH); subsequent attempts at gene therapy approvals were blocked by: (1) Jesse Gelsinger death (1999; OTC deficiency; adenovirus vector hepatotoxicity; FDA placed moratorium); (2) retroviral insertional oncogenesis in X-SCID bubble boy trials (2002-2003; Alain Fischer group France; MLV retrovirus → LMO2 insertion → T-cell leukemia in 4/9 patients); (3) recombinant DNA Advisory Committee (RAC) oversight; gene therapy in US had ZERO FDA approvals from 1990-2017 — 27 years; KYMRIAH AS GENE THERAPY BREAKTHROUGH: BLA 125706 approved August 30 2017 → FDA Commissioner Scott Gottlieb: "a new frontier in medical innovation with the ability to reprogram a patient's own cells to attack a deadly cancer" → ended 27-year approval drought; CAR-T HISTORY: Carl June's first clinical success in pediatric B-ALL: Emily Whitehead (age 7; relapsed/refractory B-ALL; bone marrow blast 70% on admission; tisagenlecleucel infusion April 2012; achieved CR May 2012; MRD-negative; still in sustained remission 2024 — 12+ years); published N Engl J Med 2013 (Grupp/Maude/Porter/June); ELIANA Phase 2 enrollment: 79 patients; ORR 81.0% (64/79); CR 60%; CRi 21%; MRD-negative (10-color flow cytometry) among responders: 79%; FDA approval based on ELIANA data; JULIET Phase 2 (adult DLBCL): ORR 52%; CR 40%; landmark DOR; FMC63 ANTI-CD19 scFv DETAIL: FMC63 is an anti-human CD19 monoclonal antibody originally described by Zola and Milburn (1987 Immunol Cell Biol); murine IgG1κ; clone FMC63 was selected from a panel of hybridomas raised against human pre-B ALL cells; CD19 binding domain: FMC63 recognizes a conformational epitope on CD19 extracellular domain (Ig-like domain; Cys3/Cys28 disulfide-stabilized fold); Kd ~2-3 nM by BLI/SPR; slow koff; USED AS scFv IN: tisagenlecleucel (tisa-cel; CTL019; BLA 125706); axicabtagene ciloleucel (axi-cel; KTE-C19; BLA 125643); lisocabtagene maraleucel (liso-cel; JCAR017; BLA 125714); brexucabtagene autoleucel (brexu-cel; KTE-X19; BLA 125703) — ALL FOUR use identical FMC63 VH/VL sequences; TONIC SIGNALING CONSEQUENCE (FMC63): as described for present-day comparison to obe-cel (SJ25C1 Kd ~28 nM): FMC63 high affinity (Kd ~2-3 nM) → slow off-rate → prolonged CAR-CD19 contact → tonic intracellular signaling via CAR construct → T-cell differentiation toward effector/exhaustion phenotype → accelerated exhaustion vs obe-cel; TISA-CEL 4-1BB ADVANTAGE VS AXI-CEL CD28: both FMC63-based; tisagenlecleucel uses 4-1BB costimulation → slower expansion (less immediate cytokine storm) → lower Grade 3+ CRS incidence (tisagenlecleucel ~7-15% in ELIANA vs axicabtagene ~13-50% Grade 3+ CRS in ZUMA-1) — 4-1BB memory bias; CRITICAL CYTOKINE RELEASE SYNDROME MANAGEMENT ADVANCE ENABLED BY TISA-CEL: FDA simultaneously approved tocilizumab (IL-6 receptor antagonist; Actemra; Genentech/Roche) August 30 2017 specifically for CRS management in CAR-T patients — co-approved on same day as Kymriah; MANUFACTURING EVOLUTION: Novartis initially manufactured tisagenlecleucel at its Morris Plains NJ facility (Penn Medicine facility for early clinical trials); commercial-scale manufacturing: Novartis AML facility (Stein Switzerland) + Lonza Houston TX CDMO; apheresis → T-cell activation → LV transduction → expansion → release → cryopreservation → QC → infusion; total manufacturing time: 3-4 weeks; PEDIATRIC B-ALL MEDICAL CONTEXT AT TIME OF APPROVAL (August 30 2017): prior SOC for R/R B-ALL after 2+ lines included: blinatumomab (BiTE; approved Dec 2014); inotuzumab ozogamicin (ADC; approved Aug 2017 same month); allo-HSCT (curative for some); tisagenlecleucel offered: single infusion → durable remission → allo-HSCT-bridging potential; FIRST-OF-ITS-KIND REIMBURSEMENT: tisagenlecleucel launched at $475,000 for one-time infusion (highest pharmaceutical price at time of approval for a one-time treatment); Novartis announced outcomes-based pricing model with CMS; NONE OF THESE — FIRST GENE THERAPY US APPROVAL HISTORIC SIGNIFICANCE, FMC63 scFv Kd ~2-3 nM CD19 EPITOPE, CD137/4-1BB TRAF2/3/5 NF-κB COSTIMULATORY, VSV-G SIN LENTIVIRAL INTEGRATION SAFETY, TOCILIZUMAB CO-APPROVAL FOR CRS, ELIANA PEDIATRIC B-ALL ORR 81% EMILY WHITEHEAD FIRST PATIENT, JULIET ADULT DLBCL ORR 52% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR BLA 125706 (NO CONVENTIONAL CAS).

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ BLA 125706 Holder AI

At Novartis Pharmaceuticals Corporation 1 Health Plaza East Hanover NJ 07936 (NOVARTIS TISAGENLECLEUCEL CONTEXT: Novartis AG (NYSE: NVS; Basel Switzerland) holds BLA 125706 for tisagenlecleucel (Kymriah) through its US subsidiary Novartis Pharmaceuticals Corporation; East Hanover NJ is Novartis US headquarters; licensed CTL019 from University of Pennsylvania Carl June lab (2012; upfront $20M + milestones; worldwide exclusive rights); Novartis executed ELIANA (B-ALL), JULIET (DLBCL), and SHINE (follicular lymphoma) pivotal trials; FDA approved August 30 2017 (B-ALL) and May 1 2018 (DLBCL); Novartis pioneered the ATC (authorized treatment center) commercialization model for CAR-T — requires institutional certification for administration (pharmacist training + nursing + physician + apheresis center + ICU backup); OCCUPATIONAL HAZARD AT NOVARTIS EAST HANOVER NJ: NIOSH HD Category 1 antineoplastic gene therapy product (living modified T cells); no conventional CAS; BLA 125706 regulatory identifier; employees in regulatory, medical affairs, commercial, and quality assurance at Novartis East Hanover NJ handle Kymriah materials and data; LV vector ancillary materials at manufacturing QC division; EMPLOYEE: 54M Novartis Pharmaceuticals East Hanover NJ VP oncology tisagenlecleucel Kymriah CTL019 BLA 125706 first CAR-T gene therapy B-ALL 22yr; CORITY NULL: BLA 125706 → no record; no CAS entry; NIOSH HD Category 1 absent; CTL019 FMC63 4-1BB lentiviral gene therapy absent; ELIANA ORR 81% absent; first gene therapy absent; ATC certification model absent).

Surface 2 — Lonza Pharma & Biotech Houston TX Commercial Manufacturing CDMO Kymriah AI

At Lonza Pharma & Biotech Houston TX 77025 (Texas Medical Center campus; LONZA TISAGENLECLEUCEL MANUFACTURING CONTEXT: Lonza's Houston facility provides commercial-scale manufacturing for tisagenlecleucel (Kymriah) as a CDMO partner for Novartis; manufacturing process: (a) APHERESIS RECEIPT: patient peripheral blood leukocytes (PBL) cryopreserved leukapheresis product shipped to Lonza Houston; (b) THAW AND ACTIVATION: PBL thawed; T cells activated with anti-CD3/CD28 MACSiBead or soluble activator + IL-2 (500 IU/mL) or IL-7+IL-15 mixture; (c) LENTIVIRAL TRANSDUCTION (DAY 2-3): CTL019 SIN LV (VSV-G pseudotyped; HIV-1 backbone; SFFV promoter; FMC63 4-1BB CD3ζ transgene) at multiplicity of infection (MOI) ~3-5; BSL-2 containment for LV; PPE: N95 + double gloves + gown + eye protection; spill containment per Lonza Houston IBC-approved SOP; no open liquid handling of undiluted LV concentrate; (d) EXPANSION: IL-2 containing media; rocking bioreactor or static flasks; 10-14 day total; (e) HARVEST: CAR+ T-cell quantification by flow cytometry (anti-FMC63 idiotype Ab staining or anti-CD19-Fc bridging assay); CD4:CD8 ratio target; viability >70%; (f) CRYOPRESERVATION: CS10 (10% DMSO + 6% HES or dextran 40) media; CryoMed controlled-rate freezer (−1°C/min to −40°C → −25°C/min to −100°C); vapor-phase LN2 storage ≤−130°C; infusion bags + cassettes; (g) RELEASE TESTING: sterility; mycoplasma; replication-competent lentivirus (RCL) assay (Mus dunni indicator cells; 3-week culture + p24 antigen ELISA); endotoxin; identity; OCCUPATIONAL HAZARDS: SIN LV (recombinant HIV-1 derived vector; no replication competent virus confirmed; BSL-2+); DMSO percutaneous penetrant; LN2 asphyxiation/cryogenic burn; NIOSH HD Cat 1 antineoplastic cell product; EMPLOYEE: 46F Lonza Pharma Houston TX process development scientist tisagenlecleucel Kymriah lentiviral FMC63 4-1BB first CAR-T manufacturing 15yr; VELOCITYEHS NULL: BLA 125706 → no record; NIOSH HD Category 1 absent; SIN LV gene therapy absent; FMC63 scFv absent; 4-1BB lentiviral absent; ELIANA absent; RCL assay absent).

Surface 3 — St. Jude Children's Research Hospital Memphis TN ELIANA Trial Pediatric B-ALL Site AI

At St. Jude Children's Research Hospital 262 Danny Thomas Place Memphis TN 38105 (ST. JUDE TISAGENLECLEUCEL CONTEXT: St. Jude Children's Research Hospital is a landmark ELIANA Phase 2 (NCT02435849) enrolling site; St. Jude Hematology/Oncology division is one of the world's foremost pediatric leukemia programs (AML/ALL programs: Wing Leung, Jeffrey Rubnitz, Brandon Triplett); ELIANA AT ST. JUDE: pediatric R/R B-ALL patients 3 months to <25 years; ELIGIBILITY: ≥2 prior lines including allo-HSCT if eligible; CD19+ B-ALL confirmed; APHERESIS: St. Jude pheresis suite (pediatric leukapheresis; weight-based minimum cell dose; children as young as 3 months — special small-bore catheter considerations for pediatric leukapheresis); LYMPHODEPLETION: fludarabine 30 mg/m²/day × 3 + cyclophosphamide 500 mg/m²/day × 2 (days −4 to −2); INFUSION: tisagenlecleucel CTL019 (cryopreserved; CS10 DMSO 10%; thaw at 37°C per St. Jude antineoplastic thaw protocol; IV over 30-60 minutes; weight-based dose 0.1-5.0 × 10⁶ CAR+ T cells/kg; flat-dose for adults); CRS MANAGEMENT CRITICAL AT ST. JUDE: pediatric CRS (Lee criteria; ASTCT revised); Grade 3+ CRS in ELIANA ~46% — substantially higher than adult DLBCL experience with tisa-cel; likely reflects higher T-cell proliferation in pediatric patients with lower total T-cell mass; tocilizumab (8 mg/kg IV; max 800 mg) first-line for Grade ≥2 CRS; siltuximab backup; corticosteroids for ICANS; IDP (intubation, dopamine, positive pressure ventilation): Grade 4 CRS criteria per ASTCT; PEDIATRIC INTENSIVE CARE UNIT (PICU): immediate availability required for all CAR-T infusions at St. Jude ATC; MRD MONITORING: bone marrow aspirate Day 28 (primary endpoint); 10-color flow cytometry; MRD-negative definition: <10⁻⁴ residual B-ALL; MRD-negative among CR: 79% in ELIANA; PHARMACY: tisagenlecleucel Kymriah (NIOSH HD Cat 1 antineoplastic gene therapy product) handled per St. Jude antineoplastic handling policy (USP 800 principles; C-PEC; double gloves; gown; eye protection); EHS INSIGHT NULL (NO CAS): BLA 125706 → "no record — standard biological handling protocol"; NIOSH HD Cat 1 absent; CTL019 gene therapy mechanism absent; ELIANA ORR 81% absent; first gene therapy absent; pediatric CRS 46% Grade 3+ management absent; EMPLOYEE: 41M St. Jude Children's Research Hospital Memphis TN pediatric hematologist ELIANA tisagenlecleucel Kymriah B-ALL CAR-T 14yr).

Integrating Glyphward into Tisagenlecleucel AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tisagenlecleucel BLA 125706 monitoring data ingestion point — before Cority at Novartis Pharmaceuticals East Hanover NJ, before VelocityEHS at Lonza Pharma & Biotech Houston TX, and before EHS Insight at St. Jude Children's Research Hospital Memphis TN. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL [no conventional CAS]; no ACGIH TLV; no NIOSH REL) [10 pts]; ONE-HUNDRED-THIRD MECHANISM CLASS — FIRST CAR-T EVER / FIRST GENE THERAPY EVER FDA APPROVED US (BLA 125706 August 30 2017; FMC63 scFv Kd ~2-3 nM; CD8α hinge+TM; CD137/4-1BB TRAF2/3/5→NF-κB; CD3ζ ITAM×3; VSV-G SIN lentiviral; ELIANA ORR 81% MRD-neg 79% Grade 3+ CRS 46%; JULIET DLBCL ORR 52%; Novartis/UPenn Carl June) [5 pts]; Novartis East Hanover NJ + Lonza Houston TX + St. Jude Memphis TN [3 pts]; FMC63 gene therapy absent; 4-1BB lentiviral absent; ELIANA absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tisagenlecleucel(bla: str, exposure_context: str) -> dict:
    """Scan tisagenlecleucel with one-hundred-third-class first-car-t-first-gene-therapy context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "bla": bla,
                "cas": None,  # autologous cell therapy — no conventional CAS
                "exposure_context": exposure_context,
                "context": "one_hundred_third_class_first_car_t_ever_first_gene_therapy_ever_fda_approved_us_ctl019_fmc63_scfv_cd8a_hinge_tm_4_1bb_cd137_traf235_nfkb_cd3z_itam3_vsvg_sin_lentiviral_eliana_orr_81pct_mrd_neg_79_grade3_crs_46_novartis_upenn_june_bla_125706"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_third_class,
    #                    first_car_t_ever, first_gene_therapy_ever,
    #                    fmc63_4_1bb_lentiviral, eliana_orr_81pct

if __name__ == "__main__":
    r = asyncio.run(scan_tisagenlecleucel(
        bla="125706",
        exposure_context="car_t_manufacturing_sin_lentiviral_fmc63_4_1bb_expansion_cryopreservation"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_third_class': True,
    #  'first_car_t_ever': True, 'first_gene_therapy_ever': True,
    #  'fmc63_4_1bb_lentiviral': True, 'eliana_orr_81pct': True}